Navigation Links
Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
Date:11/23/2009

nancial performance, including, but not limited to the following statements: the potential value of tezampanel and NGX426 in the treatment of migraine, chronic pain, and other diseases; Raptor's ability to spin out or partner the tezampanel and NGX426 pain program; and Raptor's ability to successfully develop any of its product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent the Company's forward looking statements from fruition include that Raptor may be unsuccessful in developing any products or acquiring products; that Raptor's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; that Raptor's products may not work as well as hoped or worse, that the Company's products may harm recipients; and that Raptor may not be able to raise sufficient funds for development or working capital. As well, Raptor's products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including: Raptor's current report on Form 8-K as
'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... be hosting its sixth Medical Affairs ... 12:30PM (EDT) via a virtual roundtable to discuss ... Research." Best Practices, Medical Affairs Consortium ... sharing insights about the key challenges they face. ...
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ... termination of its participation in the co-development ... STO:AZN and NYSE: AZN ).  Brodalumab, ... for patients with moderate-to-severe plaque psoriasis, psoriatic ... based on events of suicidal ideation and ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... MISSISSAUGA, Ontario, March 29, 2011 GlaxoSmithKline (GSK) and ... (TSX: VRX) announced today that the European Commission has ... (add-on) treatment of partial onset seizures (a form of ... in one side of the brain), with or without ...
... Metabolic Solutions Development Company (MSDC), a drug discovery ... treat metabolic diseases, announced today that it has ... company,s second drug candidate for the treatment of ... and placebo-controlled clinical trial will involve approximately 125 ...
Cached Medicine Technology:GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 2GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 3GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 4GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 5Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2
(Date:5/25/2015)... NY (PRWEB) May 26, 2015 ... Anne King as a 2015-2016 inductee into ... is recognized with this prestigious distinction for leadership in ... exclusively for professional women, boasting more than 700,000 members ... pleased to welcome Anne into this exceptional group of ...
(Date:5/25/2015)... City, NY (PRWEB) May 26, 2015 ... honors Laquanis Hooker as a 2015-2016 inductee into its ... recognized with this prestigious distinction for leadership in dentistry. ... professional women, boasting more than 700,000 members and over ... welcome Laquanis into this exceptional group of professional women,” ...
(Date:5/25/2015)... (PRWEB) May 26, 2015 ... honors Dr. Heather Stanley-Christian as a ... Year Circle. She is recognized with this prestigious ... nation's leading networking organization exclusively for professional women, ... operating local chapters. , "I'm pleased to welcome ...
(Date:5/25/2015)... The National Association of Professional ... as a 2015-2016 inductee into its VIP Woman of ... distinction for leadership in biomedical engineering. NAPW is the ... more than 700,000 members and over 200 operating Local ... exceptional group of professional women," said NAPW President Star ...
(Date:5/25/2015)... 25, 2015 World Patent Marketing, a ... The Preventer, a home patent that aims to protect ... , "House fires cost the United States a total ... and Creative Director of World Patent Marketing . ... homes that have no alarmed protection. With the use ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Anne King, Operating Principal at Keller Williams, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Dr. Heather Stanley-Christian, Systems Chair/Maternal Fetal Medicine at Stroger Hospital, into Its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 3
... Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of Pain ... King Extends Tender Offer Through December 19, 2008 ... N.J., Nov. 24 King Pharmaceuticals, Inc. (NYSE: KG ... that the two companies have signed a definitive merger agreement under ...
... Nov. 24 Transdel,Pharmaceuticals, Inc. (OTC Bulletin Board: ... and commercialization of non-invasive,topically targeted medications, today announced ... Company,s Board of Directors. , ... Swann, Inc., a consulting firm specializing in,marketing and ...
... resorts,are opening for the season, the Kelly Brush Foundation kicked ... the announcement of,over $20,000 in grants to ski racing clubs ... campaign to promote and improve ski racing safety. , ... of the most prestigious racing programs in,the nation including the ...
... DaVita Inc., a,leading provider of kidney care services ... kidney failure, continues to enhance DaVita.com to,make it ... well as a valuable,resource for patient education. DaVita.com/physicians ... people with chronic kidney disease and can,be found ...
... 24 ATS Medical, Inc.,(Nasdaq: ATSI ... and services, today announced that the first three ... completed by Dr. Allan,Stewart, Director, Aortic Surgery Program ... York ( http://www.ctsnet.org/home/allanstewart ) on November 17,and 18, ...
... ,Tis may be the season to be jolly but,tis ... lines that,barely move and public places stuffed with wheezing, sneezing ... makes keeping fit and healthy a bit of a challenge. ... find,Life123.com a comforting, mouse-click away. If you feel a ...
Cached Medicine News:Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 2Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 3Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 4Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 5Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 6Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 7Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 8Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 9Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 2Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 3Health News:Kelly Brush Foundation Awards Ski Racing Safety Grants 2Health News:DaVita.com Launches Physician Website 2Health News:DaVita.com Launches Physician Website 3Health News:ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States 2Health News:ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States 3Health News:Staying Healthy This Holiday Season Can be as Easy as Life123 2
Designed to determine the precise length of limbal incisions and proper alignment of closing sutures. Curved marking blade with 2 mm lines spaced 1 mm apart-measures up to 10 mm. Round knurled handle...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: